The Impact of the NOD2/CARD15 Variant (3020insC) and PSMA6 Polymorphism (-8C>G) on the Development and Outcome of Multiple Myeloma

Table 1

The characteristics of MM patients included to the study.

Variables	MM patients ()
Sex
Male	53
Female	47
Type of MM
IgG	56
IgA	25
Light chain	19
Stage according to the international staging system
I	28
II	30
III	42
Renal failure
No	82
Yes	18
The stage of chronic kidney disease (grade)
G1	30
G2	28
G3A	16
G3B	12
G4	7
G5	7
Cytogenetic changes
del(17p13.1)	14
t(4;14)	15
t(14;16)	2
Anemia grade before treatment (WHO)
Absent	28
I—mild	32
II—moderate	30
III—severe	10
Chemotherapy
Cyclophosphamide, thalidomide, dexamethasone (CTD)	49
Velcade, cyclophosphamide, dexamethasone (VCD)	29
Velcade, thalidomide, dexamethasone (VTD)	22

At diagnosis. M: mean; SD: standard deviation.